Physician profile
Gregory Locklear
NPI 1831196450
$5,931.17
in general payments reported to CMS, 2019-2025
29 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $700 · 2021: $1,044 · 2022: $838 · 2023: $724 · 2024: $865 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,538.20 | 2019-2024 | Trulance, Xifaxan, Plenvu |
| Abbvie INC. | $939.84 | 2019-2025 | |
| Ardelyx, INC. | $870.24 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $308.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $308.17 | 2020-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $218.31 | 2021-2025 | Linzess |
| Ucb, INC. | $191.12 | 2019-2020 | |
| Genzyme Corporation | $174.71 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.47 | 2019-2025 | Gattex |
| Intercept Pharmaceuticals, INC. | $171.53 | 2019-2025 | |
| Allergan, INC. | $153.36 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $130.79 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $99.97 | 2024-2025 | Zenpep |
| Echosens North America, INC. | $86.85 | 2019 | |
| Janssen Biotech, INC. | $85.91 | 2021-2023 | Stelara |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $79.24 | 2024-2025 | Voquezna |
| Celgene Corporation | $52.12 | 2021-2023 | |
| Braintree Laboratories, INC. | $49.74 | 2021-2023 | Sutab |
| Pfizer INC. | $48.16 | 2023 | |
| Gilead Sciences, INC. | $43.49 | 2024-2025 | |
| Redhill Biopharma INC. | $37.60 | 2021-2022 | |
| Qol Medical, LLC | $31.02 | 2021 | |
| Daiichi Sankyo INC. | $30.69 | 2021 | |
| Boston Scientific Corporation | $23.74 | 2019 | |
| Novo Nordisk INC | $23.15 | 2025 | Wegovy |
| Exact Sciences Corporation | $18.36 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.12 | 2023 | Cyltezo |
| Janssen Pharmaceuticals, INC | $15.07 | 2019 | |
| Horizon Therapeutics Plc | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.